^
    15d
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    1m
    TACTOPS: TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Completed, Baylor College of Medicine | Trial completion date: May 2027 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    2ms
    REGAL: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov)
    P3, N=127, Active, not recruiting, Sellas Life Sciences Group | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • decitabine • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
    4ms
    Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia. (PubMed, Blood Neoplasia)
    Although dose escalation was discontinued because of limited efficacy and lack of an exposure-BM response relationship, the observed pharmacodynamics underscore the promising potential of this class of TCBs targeting intracellular antigens. This trial was registered at www.clinicaltrials.gov as #NCT04580121.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    RG6007
    5ms
    INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=35, Completed, Inovio Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    6ms
    Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, 3D Medicines | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    WT1 (WT1 Transcription Factor)
    |
    Zeltherva (galinpepimut-S)
    7ms
    REGAL: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov)
    P3, N=128, Active, not recruiting, Sellas Life Sciences Group | Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • decitabine • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
    7ms
    INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    INO-5401 • rocakinogene sifuplasmid (INO-9012)
    9ms
    Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=29, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    melphalan • fludarabine IV • busulfan • ATA520
    9ms
    CUE-102-01: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
    P1, N=42, Completed, Cue Biopharma | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CUE-102
    11ms
    Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study. (PubMed, JTO Clin Res Rep)
    We enrolled patients with progressive or recurrent DPM treated with at least one course of pemetrexed-based chemotherapy. Median progression-free survival was 3.9 months and the median overall survival was 7.4 months. Coadministration of GPS and nivolumab reported a tolerable toxicity profile and induced immune responses in a subset of patients, but initial response and survival benefit were limited possibly owing to the small sample size.
    P1 data • Journal • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • WT1 (WT1 Transcription Factor)
    |
    Opdivo (nivolumab) • pemetrexed • Zeltherva (galinpepimut-S)
    11ms
    Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    melphalan • fludarabine IV • busulfan • ATA520